This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Yet, we know small-to-mid-sized pharma launches face a unique set of challenges.
“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. ”
VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. . Our custom system was built in 2003,” said Brochhagen.
It was interesting to see how the peer CEOs at the time of your published book Reinvent , not only from the biopharma sector but also fromCPG, chemicals, and many other verticals. Mr. Hassans public boards include Precigen, EyePoint, Cocrystal Pharma, and BridgeBio.
Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content